Yue Sun, Minxin Mao, Shengmei Tai, Mengjia Chao, Hengyu Xu, Yina Cai, Chifang Peng, Wei Ma, Zhouping Wang
{"title":"Lateral flow assay with automatic signal amplification based on delayed substrate release.","authors":"Yue Sun, Minxin Mao, Shengmei Tai, Mengjia Chao, Hengyu Xu, Yina Cai, Chifang Peng, Wei Ma, Zhouping Wang","doi":"10.1016/j.talanta.2025.127557","DOIUrl":null,"url":null,"abstract":"<p><p>The low sensitivity of Lateral flow assay (LFA) limits its application in rapid detection for trace targets. LFAs with nanozyme (nanozyme-LFA) as signal labels have demonstrated excellent performance in point of care testing (POCT). However, additional operational steps for substrate catalysis in nanozyme LFA are required, which makes the nanozyme-LFA operation complicated. In this work, we designed a LFA based on delayed substrate release (SGF-LFA), in which a commercialized glass fiber membrane embedded with substrate (SGF) was fixed at the sample pad. The SGF could automatically execute substrate delivery and catalysis, thus eventually achieving a one-step LFA operation for the nucleic acid detection of influenza A virus H1N1. In this SGF-LFA, 3,3 '- diaminobenzidine (DAB) was oxidized and deposited, producing a strong signal amplification under the catalysis of Au@PtNP nanozyme. The SGF-LFA could detect the nucleic acid of H1N1, with a linear range of 0.02-50 nM and a limit of detection (LOD) as low as 0.02 nM, which was 25-fold lower than that of the nanozyme-LFA before catalysis. In addition, the analytical performance was close to that of a manual operation mode of catalysis amplification. The application of SGF-LFA for detecting the H1N1 nucleic acid in serum samples obtained a recovery rate of 96 %-102.7 %, indicating that SGF-LFA has great potential in point-of-care testing.</p>","PeriodicalId":435,"journal":{"name":"Talanta","volume":"286 ","pages":"127557"},"PeriodicalIF":5.6000,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Talanta","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1016/j.talanta.2025.127557","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, ANALYTICAL","Score":null,"Total":0}
引用次数: 0
Abstract
The low sensitivity of Lateral flow assay (LFA) limits its application in rapid detection for trace targets. LFAs with nanozyme (nanozyme-LFA) as signal labels have demonstrated excellent performance in point of care testing (POCT). However, additional operational steps for substrate catalysis in nanozyme LFA are required, which makes the nanozyme-LFA operation complicated. In this work, we designed a LFA based on delayed substrate release (SGF-LFA), in which a commercialized glass fiber membrane embedded with substrate (SGF) was fixed at the sample pad. The SGF could automatically execute substrate delivery and catalysis, thus eventually achieving a one-step LFA operation for the nucleic acid detection of influenza A virus H1N1. In this SGF-LFA, 3,3 '- diaminobenzidine (DAB) was oxidized and deposited, producing a strong signal amplification under the catalysis of Au@PtNP nanozyme. The SGF-LFA could detect the nucleic acid of H1N1, with a linear range of 0.02-50 nM and a limit of detection (LOD) as low as 0.02 nM, which was 25-fold lower than that of the nanozyme-LFA before catalysis. In addition, the analytical performance was close to that of a manual operation mode of catalysis amplification. The application of SGF-LFA for detecting the H1N1 nucleic acid in serum samples obtained a recovery rate of 96 %-102.7 %, indicating that SGF-LFA has great potential in point-of-care testing.
期刊介绍:
Talanta provides a forum for the publication of original research papers, short communications, and critical reviews in all branches of pure and applied analytical chemistry. Papers are evaluated based on established guidelines, including the fundamental nature of the study, scientific novelty, substantial improvement or advantage over existing technology or methods, and demonstrated analytical applicability. Original research papers on fundamental studies, and on novel sensor and instrumentation developments, are encouraged. Novel or improved applications in areas such as clinical and biological chemistry, environmental analysis, geochemistry, materials science and engineering, and analytical platforms for omics development are welcome.
Analytical performance of methods should be determined, including interference and matrix effects, and methods should be validated by comparison with a standard method, or analysis of a certified reference material. Simple spiking recoveries may not be sufficient. The developed method should especially comprise information on selectivity, sensitivity, detection limits, accuracy, and reliability. However, applying official validation or robustness studies to a routine method or technique does not necessarily constitute novelty. Proper statistical treatment of the data should be provided. Relevant literature should be cited, including related publications by the authors, and authors should discuss how their proposed methodology compares with previously reported methods.